HomePHIO • NASDAQ
add
Phio Pharmaceuticals Corp
$2.18
Makalipas ang Oras ng Trabaho:(0.46%)+0.0100
$2.19
Sarado: Set 12, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$2.32
Sakop ng araw
$2.15 - $2.32
Sakop ng taon
$0.97 - $9.79
Market cap
12.48M USD
Average na Volume
157.05K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 1.24M | 17.84% |
Net na kita | -2.17M | -17.33% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -2.31M | -20.67% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 10.78M | 129.35% |
Kabuuang asset | 11.30M | 113.39% |
Kabuuang sagutin | 1.21M | -20.81% |
Kabuuang equity | 10.10M | — |
Natitirang share | 5.73M | — |
Presyo para makapag-book | 1.10 | — |
Return on assets | -46.66% | — |
Return on capital | -51.85% | — |
Cash Flow
Net change in cash
| (USD) | Hun 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -2.17M | -17.33% |
Cash mula sa mga operasyon | -2.54M | -42.94% |
Cash mula sa pag-invest | -3.00K | — |
Cash mula sa financing | 40.00K | — |
Net change in cash | -2.50M | -40.86% |
Malayang cash flow | -1.82M | -61.47% |
Tungkol
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018. Wikipedia
Itinatag
2011
Website
Mga Empleyado
5
